| Bioactivity | Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2]. | ||||||||||||
| Invitro | Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death[2].Sangivamycin (0.3 μM; 0-72 hours), shows almost maximal cytocidal (for MCF7/ADR) or cytostatic (for MCF7/WT) effects[2].Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM;), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours[2]. | ||||||||||||
| Name | Sangivamycin | ||||||||||||
| CAS | 18417-89-5 | ||||||||||||
| Formula | C12H15N5O5 | ||||||||||||
| Molar Mass | 309.28 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Sangivamycin
CAS: 18417-89-5 F: C12H15N5O5 W: 309.28
Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. San
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.